Evidence map›Paper›PMID 40936804›Full record

ArticleFrontiers in public health2025

Quality of life and its contributors among patients with homozygous familial hypercholesterolemia in China.

Mi Tang, Ziping Ye, Xueyan Zhang, Jiangjiang He, Qi Kang, Zhenqing Tang, Luya Wang, Ya Yang, Yan Yang, Shanlian Hu

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mi TangShanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.
Ziping YeSchool of Public Administration, Hainan University, Hainan, Haikou, China.
Xueyan ZhangShanghai Municipal Center for Health Promotion, Shanghai, China.
Jiangjiang HeShanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.
Qi KangShanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.
Zhenqing TangShanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.
Luya WangBeijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, China.
Ya YangBeijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, China.
Yan YangShanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai, China.
Shanlian HuSchool of Public Health, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: China is one of the countries with the largest number of patients with homozygous familial hypercholesterolemia (HoFH) in the world. Improving the quality of life and health outcomes for HoFH patients in China is of great importance. Therefore, the aim of this study is to assess the quality of life of HoFH patients in China and to investigate the factors that influence quality of life. Methods: Data were obtained from a national epidemiological survey of HoFH patients conducted by Beijing Anzhen Hospital, affiliated with Capital Medical University, during 2017-2019. The questionnaire included patient demographic information, disease information, family economic status and health-related quality of life. Quality of life was assessed using the EuroQol five-dimension three-level (EQ-5D-3L) questionnaire. Data processing and statistic tests are performed using Python libraries. Results: This investigation incorporated a sample size of 53 patients diagnosed with HoFH, with an average age of 27.92 years. It was observed that 45.28% of these patients' families were subjected to catastrophic health expenditure. The mean and median health utility scores were calculated to be 0.849 and 0.875, respectively, a figure that is significantly lower when compared to the scores of the general population. Furthermore, it was noted that 52.83% of the patients exhibited some level of difficulty or extreme difficulty in at least one dimension of the EQ-5D-3L. Significant Factors negatively affecting the quality of life of HoFH patients include the presence of atherosclerotic cardiovascular disease (ASCVD), hospitalisation in the past year, taking multiple medications, higher than average healthcare expenditure per capita, catastrophic healthcare expenditure and debt due to HoFH. After application of Benjamini-Hochberg method to minimize type 1 error, the occurrence of ASCVD and debt due to HoFH are likely to exert the most significant influence. Substantial relevance of the two factors are also evidenced by large effect sizes and adequate statistical power. Conclusions: Chinese patients with HoFH showed lower quality of life than the general population. Policy makers should consider the policy that improves early diagnosis, employment prospects, and the availability of HoFH-related interventions and provision of financial assistance for patients suffering from HoFH.

Indexed as

Hyperlipoproteinemia Type IIQuality of LifeAdolescentAdultChinaFemaleHealth ExpendituresHomozygoteHumansMaleMiddle AgedSurveys and QuestionnairesYoung AdultChinaepidemiological surveyhomozygous familial hypercholesterolemiaquality of liferare disease

Identifiers

PMID40936804
PMCPMC12421902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.